Solid Biosciences Inc. (SLDB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.42+0.06 (+0.94%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 6.36 |
| Open | 6.25 |
| Bid | 6.21 x 1800 |
| Ask | 6.60 x 900 |
| Day's Range | 6.11 - 6.49 |
| 52 Week Range | 1.93 - 8.56 |
| Volume | 459,693 |
| Avg. Volume | 1,850,281 |
| Market Cap | 544.247M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.05 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.70 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Investor's Business Daily
Pfizer Stock 2021: A Lean, Mean, Covid-Fighting Machine?
Pfizer sees coronavirus vaccines as a "durable" business, one executive said recently. But don't expect Pfizer stock to be hung up on Covid-19 in 2021. The company sees plenty of catalysts.
- Barrons.com
Sarepta Stock Dropped 50% After Gene-Therapy Setback. What to Do Now.
The shares lost about half of their value after the company disclosed disappointing trial results for a gene therapy meant to cure Duchenne muscular dystrophy.
- Motley Fool
Why Solid Biosciences Stock Is Sinking Today
The drop came after Sarepta Therapeutics (NASDAQ: SRPT) reported disappointing clinical results for experimental gene therapy SRP-9001 in treating rare genetic disease Duchenne muscular dystrophy (DMD). Sarepta's problem was that SRP-9001 didn't meet the primary functional endpoint of its clinical study. Just because SRP-9001 failed in a clinical study doesn't necessarily mean that SGT-001 will.
© 2021 Verizon Media. All rights reserved.
